槐耳颗粒对肝细胞癌根治性切除术后复发的影响:一项多中心随机临床试验
这项多中心、随机、对照IV期试验将1044例肝细胞癌根治性切除术后患者按2:1随机分配接受槐耳颗粒(n=686)或无进一步治疗(对照组n=316),最长96周。槐耳组与对照组平均无复发生存期分别为75.5周和68.5周(HR 0.67;95%CI 0.55至0.81),无复发生存率分别为62.39%和49.05%(95%CI 6.74至19.94;p=0.0001),总生存率分别为95.19%和91.46%(95%CI 0.26至7.21;p=0.0207),肝外复发率分别为8.60%和13.61%(95%CI -12.59至-2.50;p=0.0018)。
要点
- 槐耳组平均无复发生存期75.5周 vs 对照组68.5周(HR 0.67;95%CI 0.55至0.81)。
- 槐耳组无复发生存率62.39% vs 对照组49.05%(95%CI 6.74至19.94;p=0.0001)。
- 槐耳组总生存率95.19% vs 对照组91.46%(95%CI 0.26至7.21;p=0.0207),肝外复发率8.60% vs 13.61%(95%CI -12.59至-2.50;p=0.0018)。
核心结论
- 这是首个全国性多中心研究,涉及39个中心和1044例患者,证明槐耳颗粒作为肝细胞癌根治性肝切除术后辅助治疗的有效性,显示槐耳组无复发生存期显著延长且肝外复发减少。
研究设计与样本
- 多中心、随机、对照、IV期试验,共1044例患者按2:1比例随机分配接受槐耳颗粒(n=686)或无进一步治疗(对照组n=316),最长治疗96周。
主要发现
- 槐耳组与对照组平均无复发生存期分别为75.5周和68.5周(HR 0.67;95%CI 0.55至0.81)。
- 槐耳组与对照组无复发生存率分别为62.39%和49.05%(95%CI 6.74至19.94;p=0.0001)。
- 槐耳组与对照组总生存率分别为95.19%和91.46%(95%CI 0.26至7.21;p=0.0207)。
- 槐耳组与对照组肿瘤肝外复发率分别为8.60%和13.61%(95%CI -12.59至-2.50;p=0.0018)。
关键数值与推荐
- 主要终点为无复发生存期(RFS);次要终点包括总生存期(OS)和肿瘤肝外复发率(ERR)。
临床怎么用
- 原文结论认为槐耳颗粒作为肝细胞癌根治性肝切除术后辅助治疗有效,显著延长无复发生存期并减少肝外复发。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: There is little evidence that adjuvant therapy after radical surgical resection of hepatocellular carcinoma (HCC) improves recurrence-free survival (RFS) or overall survival (OS). We conducted a multicentre, randomised, controlled, phase IV trial evaluating the benefit of an aqueous extract of Trametes robinophila Murr (Huaier granule) to address this unmet need. DESIGN AND RESULTS: A total of 1044 patients were randomised in 2:1 ratio to receive either Huaier or no further treatment (controls) for a maximum of 96 weeks. The primary endpoint was RFS. Secondary endpoints included OS and tumour extrahepatic recurrence rate (ERR). The Huaier (n=686) and control groups (n=316) had a mean RFS of 75.5 weeks and 68.5 weeks, respectively (HR 0.67; 95% CI 0.55 to 0.81). The difference in the RFS rate between Huaier and control groups was 62.39% and 49.05% (95% CI 6.74 to 19.94; p=0.0001); this led to an OS rate in the Huaier and control groups of 95.19% and 91.46%, respectively (95% CI 0.26 to 7.21; p=0.0207). The tumour ERR between Huaier and control groups was 8.60% and 13.61% (95% CI -12.59 to -2.50; p=0.0018), respectively. CONCLUSIONS: This is the first nationwide multicentre study, involving 39 centres and 1044 patients, to prove the effectiveness of Huaier granule as adjuvant therapy for HCC after curative liver resection. It demonstrated a significant prolongation of RFS and reduced extrahepatic recurrence in Huaier group. TRIAL REGISTRATION: NCT01770431; Post-results.
引用
- Chen Q, Shu C, Laurence AD, et al. Effect of Huaier granule on recurrence after curative resection of HCC: a multicentre, randomised clinical trial. Gut. 2018. PMID: 29802174. doi:10.1136/gutjnl-2018-315983
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。